Is there a retatrutide pill? What the trials actually used
Is there a retatrutide pill? No, and nothing in the clinical programme points to one. Retatrutide (research code LY3437943) is an investigational triple agonist of the GIP, GLP-1 and glucagon receptors, and every efficacy trial has given it as a subcutaneous injection once a week. That includes the phase 2 obesity trial (Jastreboff et al., New England Journal of Medicine, 2023), the phase 2 type 2 diabetes trial (Rosenstock et al., The Lancet, 2023) and the phase 3 TRIUMPH and TRANSCEND programmes that reported through 2026.
We checked the ClinicalTrials.gov registry at the time of writing (September 2026). Of the retatrutide studies listed there, the intervention is described as a subcutaneous injection. The only studies that mention oral dosing are drug interaction studies, where another medicine (for example metoprolol) was swallowed alongside injected retatrutide to see whether retatrutide changed how it was absorbed. None tests a retatrutide tablet or capsule.
Lilly's own plan confirms the direction: its July 2026 announcement said the phase 3 package was complete and that it intends to file a US application in the first quarter of 2027. That filing is for the weekly injection. For the background on the molecule, see our explainer on what retatrutide is and how the triple agonist works.
Why retatrutide oral dosing does not work: the peptide problem
Retatrutide is a 39 amino acid peptide with a molecular weight of roughly 4,700, carrying a C20 fatty diacid side chain that binds albumin in the blood and gives it the long half-life that makes weekly dosing possible. Those same features make oral retatrutide a very hard proposition.
- Digestion. The stomach and small intestine exist to break proteins down. Pepsin, trypsin and chymotrypsin cut peptide bonds, and a peptide swallowed without protection is largely reduced to fragments before it reaches the bloodstream.
- Size. The gut wall lets small, fat-soluble molecules through easily. A molecule of around 4,700 is many times larger than a typical tablet drug, and it cannot slip between intestinal cells in any useful quantity.
- Charge and water solubility. Peptides carry charged side chains and like water, which is the opposite of what passes through a cell membrane.
This is why insulin, semaglutide, tirzepatide and retatrutide were all developed first as injections. Injecting under the skin bypasses the gut completely. It is a chemistry constraint, not a marketing choice, and it is the reason a retatrutide pill cannot simply be made by pressing the powder into a tablet.
The one peptide GLP-1 tablet: oral semaglutide and SNAC
The only way a GLP-1 peptide has been made to work by mouth is semaglutide, and the method shows how hard it is. Rybelsus, Novo Nordisk's semaglutide tablet, co-formulates the peptide with salcaprozate sodium (SNAC). SNAC raises the local pH around the tablet, protecting semaglutide from pepsin, and helps it cross the stomach lining, which is where most absorption happens.
Even with SNAC, the US prescribing information puts the absolute bioavailability of the original Rybelsus tablets at about 0.4 to 1%. Put simply, more than 99% of the peptide in each tablet never reaches the circulation, so the tablet has to contain far more semaglutide than a weekly injection does, and it has to be taken under strict fasting conditions for absorption to be consistent. In Australia, Rybelsus is registered on the ARTG for type 2 diabetes; the TGA approved it in 2022. In December 2025 the US FDA approved a higher-strength oral semaglutide tablet (the Wegovy pill) for weight management, based on the OASIS 4 trial.
Two points matter here. Semaglutide's tablet took years of formulation work specific to that molecule, and nothing equivalent has been published for retatrutide. And a supplier who presses retatrutide into a capsule without an absorption enhancer and a validated formulation is selling something with no evidence that any of it is absorbed.
Orforglipron: Lilly's oral option is a different drug
A lot of searches for oral retatrutide are probably people who have heard that Lilly has a weight loss pill. It does, but it is not retatrutide. Orforglipron is a small molecule, not a peptide, with a molecular weight of about 880, and it activates the GLP-1 receptor only. Because it is a small molecule it survives digestion and is absorbed like an ordinary tablet drug, without the fasting rules oral semaglutide needs.
- Trial results. In ATTAIN-1 (Wharton et al., New England Journal of Medicine, 2025), 3,127 adults with obesity and without diabetes were randomised to orforglipron 6, 12 or 36 mg daily or placebo. At 72 weeks mean weight change was minus 7.5%, 8.4% and 11.2% against minus 2.1% on placebo. Gastrointestinal effects were the most common adverse events.
- United States. The FDA approved orforglipron as Foundayo on 1 April 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition.
- Australia. Lilly lodged an application with the TGA, which lists it under the proposed name Nexvound as a prescription medicine under evaluation for weight management and type 2 diabetes. At the time of writing it is not on the ARTG. Check the TGA's current listing for its status.
So the honest comparison is retatrutide (triple agonist, weekly injection, investigational) against orforglipron (single GLP-1 agonist, daily tablet, approved in the US). Cross-trial numbers are not a fair test, but orforglipron's weight loss in ATTAIN-1 was smaller than retatrutide's in its phase 2 and phase 3 trials. Our comparison of retatrutide against tirzepatide covers the injectable side of that picture.
Why retatrutide tablets sold online should be treated as suspect
If no oral retatrutide exists in any trial, what is in the retatrutide tablets and capsules advertised online? Nobody selling them has published an answer. There is no validated oral formulation to copy, no absorption data, and no reference standard for what a working retatrutide tablet would contain.
Australian regulators have already shown what goes wrong with unverified retatrutide. In September 2026 the TGA reported testing a product labelled retatrutide after a patient was hospitalised with a torn oesophagus following uncontrollable vomiting. The product contained no retatrutide at all. It held undeclared semaglutide, at roughly eight times the level found in semaglutide products the TGA has assessed. The TGA's advice is that retatrutide accessed outside a clinical trial could be counterfeit and should not be used outside a trial setting. Earlier in 2026, the Victorian Department of Health reported cases of acute liver injury in people using unapproved products labelled retatrutide.
A tablet or capsule makes verification harder, not easier. Fillers, binders and coatings complicate testing, and a pill offers no clue about the peptide's condition. Our view is simple: treat any retatrutide pill as unverified until the seller shows mass spectrometry identity data for that exact lot, and even then there is no published evidence that the peptide is absorbed by mouth. More on the Australian position is in is retatrutide available in Australia.
What Chainwell Peptide supplies instead, and why
Chainwell Peptide does not sell retatrutide tablets, capsules or drops, because there is no published evidence behind any oral format. We supply retatrutide in the form that matches the literature: a lyophilised (freeze-dried) peptide for laboratory research.
- Retatrutide research vials in 10, 20 and 30 mg fills. Freeze-dried peptide keeps best while it stays dry, and the lot number on each vial matches its certificate on the COA lookup page.
- The retatrutide research pen, a 10 mg, 3 mL pen format for laboratories that prefer it to a vial.
- The retatrutide starter kit, available with a 10, 20 or 30 mg vial. Bacteriostatic water for reconstitution is also sold on its own.
Every lot is tested by an independent laboratory for identity by mass spectrometry and purity by HPLC; our quality testing process explains the methods. For concentration maths when reconstituting a vial in the lab, use the retatrutide reconstitution calculator. Orders paid before 3pm AEST on a business day are dispatched the same day by tracked post from within Australia.
Research use only: all Chainwell Peptide products are sold for laboratory research, not for human or veterinary use, and nothing on this page is dosing or administration advice. Browse the full metabolic research peptides range for related compounds.
Frequently asked questions
Is there a retatrutide pill?
+
No. Every retatrutide trial published or registered so far uses a once-weekly subcutaneous injection, and Eli Lilly has not announced an oral formulation. Products sold online as retatrutide pills or tablets have no clinical data behind them, and the TGA has warned that retatrutide outside a clinical trial could be counterfeit.
Can retatrutide be taken orally?
+
There is no published evidence that it can. Retatrutide is a 39 amino acid peptide that digestive enzymes break down and the gut wall barely absorbs. The only GLP-1 peptide that works as a tablet, semaglutide, needs the absorption enhancer SNAC and still reaches only about 0.4 to 1% bioavailability in its original formulation.
Is orforglipron the same as oral retatrutide?
+
No. Orforglipron is a separate Eli Lilly drug: a small molecule that activates only the GLP-1 receptor and is taken as a daily tablet. Retatrutide is an injected peptide acting on three receptors. The FDA approved orforglipron as Foundayo in April 2026; in Australia it is under TGA evaluation at the time of writing.
Are retatrutide tablets sold online real?
+
There is no way to know without testing, and no validated retatrutide tablet exists to compare them against. In September 2026 the TGA tested a product labelled retatrutide and found no retatrutide, only a large dose of undeclared semaglutide. Treat any retatrutide tablet as unverified unless lot-specific mass spectrometry data is provided.
Why is retatrutide only available as an injection?
+
Because it is a large peptide. Stomach and intestinal enzymes break peptide bonds, and a molecule of roughly 4,700 in weight cannot cross the gut wall in useful amounts. Injection under the skin avoids the gut entirely, which is why retatrutide, like tirzepatide and injectable semaglutide, has been studied only in that form.
